Key result
GnRH agonists may impair myocardial angiogenesis by reducing VEGF expression, potentially worsening hypoxia and increasing the risk of cardiac failure in patients with preexisting cardiac disease.
Why the study?
GnRH agonists were associated with increased cardiovascular risk in prostate cancer patients, but studies aiming to elucidate the mechanisms behind these cardiovascular effects are rare.
Do GnRH agonists increase the risk of cardiac failure by impairing myocardial angiogenesis in patients with prostate cancer and preexisting cardiac disease?
Do GnRH agonists increase the risk of cardiac failure by impairing myocardial angiogenesis in patients with prostate cancer and preexisting cardiac disease?
GnRH agonists may increase the risk of heart failure in prostate cancer patients with preexisting cardiac disease by inhibiting myocardial angiogenesis.
Answers are grounded in this paper and cite their sources.
Caution advised with GnRH agonists in prostate cancer patients with preexisting cardiac disease; hypothesis-generating for angiogenesis effects, needing prospective validation.
Gonadotropin-releasing hormone agonists were described as anti-angiogenic factors in tumors. Simultaneously they were associated with increased cardiovascular risk in patients treated for prostate cancer, especially in those with preexisting cardiac disease. Studies aiming to elucidate the mechanisms by which androgen deprivation therapy causes cardiovascular effects are rare. We believe that gonadotropin-releasing hormone agonists can impair myocardial angiogenesis. That, in patients with myocardial disease can deepen hypoxia, significantly worsen the condition of the myocardium, and therefore increase the risk of cardiac failure. Careful assessment of the myocardial status and consequent timing and typing of therapy can minimalize the adverse effects. Ideally through close cooperation between cardiologists and oncologists (Fig. 1, Ref. 25).
No takes yet. Share an insight, caveat, or question.
Valaskova et al. (2019) conducted a review in Prostate cancer with cardiovascular risk. GnRH agonists was evaluated. GnRH agonists may impair myocardial angiogenesis by reducing VEGF expression, potentially worsening hypoxia and increasing the risk of cardiac failure in patients with preexisting cardiac disease.
Synapse has enriched 10 related papers. Consider them for comparative context: